The pharmaceutical company’s offering was split in eight parts, with maturities ranging from three to 40 years, the people said, asking not to be identified discussing private details. The spread for the longest portion of the deal — a $1 billion note maturing in 2065 — tightened to 1 percentage point above Treasuries, from 1.2 percentage points initially, the people added. ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
